{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T20:34:52Z","timestamp":1754598892400},"reference-count":20,"publisher":"Galenos Yayinevi","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tjh"],"DOI":"10.4274\/tjh.galenos.2023.2022.0452","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T11:33:13Z","timestamp":1677583993000},"page":"37-42","source":"Crossref","is-referenced-by-count":3,"title":["Myeloproliferative Neoplasms and Aspirin: Does Increased Platelet Turnover Matter?"],"prefix":"10.4274","volume":"40","author":[{"given":"Ilg\u0131n","family":"Ko\u00e7ak G\u00f6kt\u00fcrk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u015f\u0131l","family":"Erdo\u011fan \u00d6z\u00fcnal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alican","family":"G\u00f6kt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Hakan","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcven","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga Meltem","family":"Akay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erman","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1055\/s-0039-1693477","article-title":"Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms","volume":"45","author":"DRJ","year":"2019","unstructured":"1. Arachchillage DRJ, Laffan M. Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms. Semin Thromb Hemost 2019;45:604-611.","journal-title":"Semin Thromb Hemost"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","unstructured":"2. Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, Tognoni G, Marchioli R; European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP). Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007;109:2446-2452.","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.patbio.2004.02.007","article-title":"A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP)","volume":"52","author":"Finazzi","year":"2004","unstructured":"3. Finazzi G. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). Pathol Biol (Paris) 2004;52:285-258.","journal-title":"Pathol Biol (Paris)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","unstructured":"4. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-124.","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1182\/blood.2019004596","article-title":"A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia","volume":"136","author":"Rocca","year":"2020","unstructured":"5. Rocca B, Tosetto A, Betti S, Soldati D, Petrucci G, Rossi E, Timillero A, Cavalca V, Porro B, Iurlo A, Cattaneo D, Bucelli C, Dragani A, Di Ianni M, Ranalli P, Palandri F, Vianelli N, Beggiato E, Lanzarone G, Ruggeri M, Carli G, Elli EM, Carpenedo M, Randi ML, Bertozzi I, Paoli C, Specchia G, Ricco A, Vannucchi AM, Rodeghiero F, Patrono C, De Stefano V. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood 2020;136:171-182.","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7326\/M17-0284","article-title":"Benefits and risks of antithrombotic therapy in essential thrombocythemia: a systematic review","volume":"167","author":"Chu","year":"2017","unstructured":"6. Chu DK, Hillis CM, Leong DP, Anand SS, Siegal DM. Benefits and risks of antithrombotic therapy in essential thrombocythemia: a systematic review. Ann Intern Med 2017;167:170-180.","journal-title":"Ann Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S0140-6736(06)68040-9","article-title":"Aspirin resistance","volume":"367","author":"GJ","year":"2006","unstructured":"7. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006;367:606-617.","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","article-title":"Profile and prevalence of aspirin resistance in patients with cardiovascular disease","volume":"88","author":"Gum","year":"2001","unstructured":"8. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235.","journal-title":"Am J Cardiol"},{"key":"ref8","unstructured":"9. Sadiq PA, Puri A, Dixit M, Ghatak A, Dwivedi SK, Narain VS, Saran RK, Puri VK. Profile and prevalence of aspirin resistance in Indian patients with coronary artery disease. Indian Heart J 2005;57:658-661."},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Galvez C, Stein BL. Thrombocytosis and thrombosis: is there really a correlation? Curr Hematol Malig Rep 2020;15:261-267.","DOI":"10.1007\/s11899-020-00588-z"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1093\/eurheartj\/ehm226","article-title":"A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease","volume":"28","author":"Lordkipanidze","year":"2007","unstructured":"11. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-1708.","journal-title":"Eur Heart J"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Dussaillant NG, Zapata MM, Fardella BP, Conte LG, Cuneo VM. Frequency and characteristics of aspirin resistance in Chilean cardiovascular patients. Revista Medica de Chile 2005;133:409-417.","DOI":"10.4067\/S0034-98872005000400003"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.3324\/haematol.2010.027102","article-title":"Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance","volume":"95","author":"Renda","year":"2010","unstructured":"13. Renda G, Zurro M, Malatesta G, Ruggieri B, De Caterina R. Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance. Haematologica 2010;95:2095-2101.","journal-title":"Haematologica"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target","volume":"119","author":"Pascale","year":"2012","unstructured":"14. Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F, Pocaterra D, Ragazzoni E, Rolandi G, Rocca B, Patrono C. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012;119:3595-3603.","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.thromres.2016.04.006","article-title":"Multiple electrode aggregometry is an adequate method for aspirin response testing in myeloproliferative neoplasms and differentiates the mechanisms of aspirin resistance","volume":"142","author":"Gillet","year":"2016","unstructured":"15. Gillet B, Ianotto JC, Mingant F, Didier R, Gilard M, Ugo V, Lippert E, Galinat H. Multiple electrode aggregometry is an adequate method for aspirin response testing in myeloproliferative neoplasms and differentiates the mechanisms of aspirin resistance. Thromb Res 2016;142:26-32.","journal-title":"Thromb Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1182\/blood-2009-08-236679","article-title":"The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy","volume":"115","author":"Dragani","year":"2010","unstructured":"16. Dragani A, Pascale S, Recchiuti A, Mattoscio D, Lattanzio S, Petrucci G, Mucci L, Ferrante E, Habib A, Ranelletti FO, Ciabattoni G, Dav\u00ec G, Patrono C, Rocca B. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood 2010;115:1054-1061.","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/09537104.2017.1361018","article-title":"Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms","volume":"29","author":"Perrier-Cornet","year":"2018","unstructured":"17. Perrier-Cornet A, Ianotto JC, Mingant F, Perrot M, Lippert E, Galinat H. Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms. Platelets 2018;29:723-728.","journal-title":"Platelets"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/bmj.326.7380.82","article-title":"Platelet responsiveness to aspirin in patients with hyperlipidaemia","volume":"326","author":"Friend","year":"2003","unstructured":"18. Friend M, Vucenik I, Miller M. Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 2003;326:82-83.","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1161\/01.CIR.96.1.69","article-title":"Evidence derived from the study of peripheral arterial disease","volume":"96","author":"Davi","year":"1997","unstructured":"19. Davi G, Gresele P, Violi F, Basili S, Catalano M, Giammarresi C, Volpato R, Nenci GG, Ciabattoni G, Patrono C. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 1997;96:69-75.","journal-title":"Circulation"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00125-007-0898-3","article-title":"Aspirin resistance and diabetes mellitus","volume":"51","author":"Ajjan","year":"2008","unstructured":"20. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia 2008;51:385-390.","journal-title":"Diabetologia"}],"container-title":["Turkish Journal of Hematology"],"original-title":[],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T12:38:52Z","timestamp":1678192732000},"score":1,"resource":{"primary":{"URL":"https:\/\/jag.journalagent.com\/z4\/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-90008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3,3]]}},"URL":"https:\/\/doi.org\/10.4274\/tjh.galenos.2023.2022.0452","relation":{},"ISSN":["1300-7777","1308-5263"],"issn-type":[{"value":"1300-7777","type":"print"},{"value":"1308-5263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]}}}